Neurotrophic paths in the treatment of depression

Journal of Psychiatry and Neuroscience

Volumn 38, Issue 5, 2013, Pages 291-293

  Hayley, Shawn ^a   Anisman, Hymie ^a  

^a CARLETON UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; ERYTHROPOIETIN; FIBROBLAST GROWTH FACTOR 2; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; KETAMINE; MEMANTINE; NEUROTROPHIC FACTOR; NEUROTROPHIN 3; RILUZOLE; SEROTONIN TRANSPORTER; VASCULOTROPIN;

BLOOD BRAIN BARRIER; BRAIN DISEASE; DEPRESSION; DNA POLYMORPHISM; EDITORIAL; ELECTRIC SHOCK; GENE EXPRESSION; HIPPOCAMPUS; HUMAN; META ANALYSIS (TOPIC); NERVE CELL PLASTICITY; NONHUMAN; SYNAPTOGENESIS;

ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSIVE DISORDER, MAJOR; ERYTHROPOIETIN; HUMANS; NERVE GROWTH FACTORS; NEURONAL PLASTICITY;

EID: 84883237677     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.130146     Document Type: Editorial

References (34)

1. Duric V, Duman RS. Depression and treatment response: dynamic interplay of signaling pathways and altered neural processes. Cell Mol Life Sci 2013;70:39-53.
2. Warner-Schmidt JL, Duman RS. VEGF as a potential target for thera-peutic intervention in depression. Curr Opin Pharmacol 2008; 8:14-9.
3. MacQueen G, Frodl T. The hippocampus in major depression: Evidence for the convergence of the bench and bedside in psychiatric research? Mol Psychiatry 2011;16:252-64.
4. Ota KT, Duman RS. Environmental and pharmacological modulations of cellular plasticity: role in the pathophysiology and treatment of depression. Neurobiol Dis 2013;57:28-37.
5. Duman RS. Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: stress and depression. Dialogues Clin Neurosci 2009;11:239-55.
6. Groves JO. Is it time to reassess the BDNF hypothesis of depression? Mol Psychiatry 2007;12:1079-88.
7. Gaughran F, Payne J, Sedgwick PM, et al. Hippocampal FGF-2 and FGFR1 mRNA expression in major depression, schizophrenia and bipolar disorder. Brain Res Bull 2006;70:221-7.
8. Siegel GJ, Chauhan NB. Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res Rev 2000;33:199-227.
9. Jiang C, Salton SR. The role of neurotrophins in major depressive disorder. Transl Neurosci 2013;4:46-58.
10. Zou Y-F, Ye D-Q, Feng X-L, et al. Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder. Eur Neuropsychopharmacol 2010; 20:535-44.
11. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003;301:386-9.
12. Roth TL, Sweatt JD. Epigenetic marking of the BDNF gene by early-life adverse experiences. Horm Behav 2011;59:315-20.
13. Elzinga BM, Molendijk ML, Boudewijn RC, et al. The impact of childhood abuse and recent stress on serum brain-derived neuro-trophic factor and the moderating role of BDNF Val66Met. Psychopharmacology (Berl) 2011;214:319-28.
14. Perea CS, Paternina AC, Gomez Y, et al. Negative affectivity moderated by BDNF and stress response. J Affect Disord 2012;136:767-74.
15. Buchmann AF, Hellweg R, Rietschel M, et al. BDNF Val 66 Met and 5-HTTLPR genotype moderate the impact of early psychosocial adversity on plasma brain-derived neurotrophic factor and depressive symptoms: a prospective study. Eur Neuropsychopharmacol 2012 Oct. 8 [Epub ahead of print].
16. Grabe HJ, Schwahn C, Mahler J, et al. Genetic epistasis between the brain-derived neurotrophic factor Val66Met polymorphism and the 5-HTT promoter polymorphism moderates the susceptibility to depressive disorders after childhood abuse. Prog Neuropsychopharmacol Biol Psychiatry 2012;36:264-70.
17. Belsky J, Jonassaint C, Pluess M, et al. Vulnerability genes or plasticity genes? Mol Psychiatry 2009;14:746-54.
18. Caldwell W, McInnis OA, McQuaid RJ, et al. The role of the Val66Met polymorphism of the brain derived neurotrophic factor gene in coping strategies relevant to depressive symptoms. PLoS ONE 2013;8:e65547.
19. Schmidt HD, Duman RS. Peripheral BDNF produces antidepressantlike effects in cellular and behavioral models. Neuropsychopharmacology 2010;35:2378-91.
20. Baseri B, Choi JJ, Deffieux T, et al. Activation of signaling pathways following localized delivery of systemically administered neurotrophic factors across the blood-brain barrier using focused ultrasound and microbubbles. Phys Med Biol 2012;57:N65-81.
21. Guo W, Robbins MT, Wei F, et al. Supraspinal brain-derived neuro-trophic factor signaling: a novel mechanism for descending pain facilitation. J Neurosci 2006;26:126-37.
22. Govindarajan A, Rao BS, Nair D, et al. Transgenic brain-derived neurotrophic factor expression causes both anxiogenic and anti-depressant effects. Proc Natl Acad Sci U S A 2006;103:13208-13.
23. Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science 2012;338:68-72.
24. Owen RT. Glutamatergic approaches in major depressive disorder: focus on ketamine, memantine and riluzole. Drugs Today (Barc) 2012; 48:469-78.
25. Sanchez PE, Fares RP, Risso JJ, et al. Optimal neuroprotection by erythropoietin requires elevated expression of its receptor in neur-ons. Proc Natl Acad Sci U S A 2009;106:9848-53.
26. Banks WA, Jumbe NL, Farrell CL, et al. Passage of erythropoietic agents across the blood-brain barrier: a comparison of human and murine erythropoietin and the analog darbepoetin alfa. Eur J Pharmacol 2004;505:93-101.
27. Sargin D, Friedrichs H, El-Kordi A, et al. Erythropoietin as neuroprotective and neuroregenerative treatment strategy: comprehensive overview of 12 years of preclinical and clinical research. Best Pract Res Clin Anaesthesiol 2010;24:573-94.
28. Girgenti MJ, Hunsberger J, Duman CH, et al. Erythropoietin induction by electroconvulsive seizure, gene regulation, and antidepressant-like behavioral effects. Biol Psychiatry 2009;66:267-74.
29. Miskowiak KW, Vinberg M, Harmer CJ, et al. Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression. Psychopharmacology (Berl) 2012;219:687-98.
30. Leconte C., Bihel E., Lepelletier F.X., et al. Comparison of the effects of erythropoietin and its carbamylated derivative on behaviour and hippocampal neurogenesis in mice. Neuropharmacology 2011;60:354-64.
31. Yan HC, Cao X, Gao TM, et al. Promoting adult hippocampal neuro genesis: a novel strategy for antidepressant drug screening. Curr Med Chem 2011;18:4359-67.
32. Byts N, Samoylenko A, Fasshauer T, et al. Essential role for Stat5 in the neurotrophic but not in the neuroprotective effect of eryth-ropoietin. Cell Death Differ 2008;15:783-792.
33. Duman CH, Schlesinger L, Russell DS, et al. Voluntary exercise produces antidepressant and anxiolytic behavioral effects in mice. Brain Res 2008;1199:148-58.
34. Ravindran AV, da Silva TL. Complementary and alternative ther-apies as add-on to pharmacotherapy for mood and anxiety disorders: a systematic review. J Affect Disord 2013 June 11 [Epub ahead of print].